Filler and In-Vivo - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Filler

In-Vivo

SkinVive by Juvéderm: The New Dermal Filler Coming to the US

XTalks

MAY 22, 2023

“This unique product is a result of our vast experience in hyaluronic acid science and complements our current collection of hyaluronic acid products, with the Juvéderm collection of fillers and SkinMedica topicals.” . “Skin quality is among the top concerns my patients express when seeking aesthetic treatments. .

Filler

Filler FDA Approval Dermatology Production

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

The Pharma Data

DECEMBER 27, 2020

Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. An in vivo toxicity study by staining of the cartilage showed TLC599 to be cartilage sparing compared to current treatments. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec.

Trials

Trials Clinical Trials Clinical Trials Containment

SkinVive by Juvéderm: The New Dermal Filler Coming to the US

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

Stay Connected